© Reuters

By Dhirendra Tripathi

Investing – BioNTech (NASDAQ:) shares were up more than 6% Friday after its proposal to be allowed to provide COVID-19 vaccines for 12- to 15-year-olds in the UK got past the country’s medicine regulator.

The proposal now needs the nod of the UK’s Joint Committee on Vaccination and Immunization. It will go to the Health and Social Care department from there.

The company had last Friday it secured approval from the European Medicines Agency for use of its COVID-19 vaccine in children of the same age group.

Children aged 12-15 years are already receiving the shot in the U.S.

Pfizer and BioNTech have so far committed to delivering 2.4 billion doses of the vaccine through 2023 to various countries.

The vaccine is based on BioNTech’s proprietary mRNA technology. The German company has a tie-up with Pfizer (NYSE:) to make and market the vaccine in geographies mutually distributed between the two.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Source link


Please enter your comment!
Please enter your name here